0.78
-0.003(-0.38%)
Currency In USD
| Previous Close | 0.78 |
| Open | 0.78 |
| Day High | 0.79 |
| Day Low | 0.78 |
| 52-Week High | 1.99 |
| 52-Week Low | 0.45 |
| Volume | 98,510 |
| Average Volume | 308,567 |
| Market Cap | 59.71M |
| PE | -1.52 |
| EPS | -0.51 |
| Moving Average 50 Days | 0.8 |
| Moving Average 200 Days | 0.95 |
| Change | -0 |
If you invested $1000 in Cue Biopharma, Inc. (CUE) since IPO date, it would be worth $66.81 as of September 09, 2025 at a share price of $0.777. Whereas If you bought $1000 worth of Cue Biopharma, Inc. (CUE) shares 5 years ago, it would be worth $46.55 as of September 09, 2025 at a share price of $0.777.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference
GlobeNewswire Inc.
Aug 21, 2025 12:00 PM GMT
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
GlobeNewswire Inc.
Aug 13, 2025 12:00 PM GMT
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer
GlobeNewswire Inc.
Jul 16, 2025 12:00 PM GMT
Additional complete response (CR) observed in patient with multiple tumorsConfirmed overall response rate (ORR) of 50% in patients with combined positive score (CPS) ≥1, including 50% ORR in patients with low CPS (1-19)12-month overall survival of 88